CACACE, ENRICO

Corda M

ERA, BENEDETTA

FAIS, ANTONELLA

Molin L

RUGGIERO, VALERIA

Utzeri S.

English

Archivio istituzionale della ricerca - Università di Cagliari

Clin Chem Lab Med 2014; 52(9): e207–e210Letter to the EditorValeria Ruggiero, Benedetta Era, Enrico Cacace, Laura Molin, Marcella Corda, Antonella Fais* and Stefania UtzeriA preliminary study on serum proteomics in fibromyalgia syndromeKeywords: fibromyalgia syndrome; serum proteomics; 2D electrophoresis.DOI 10.1515/cclm-2014-0086Received January 23, 2014; accepted March 5, 2014; previously  published online April 3, 2014To the Editor,Fibromyalgia syndrome (FMS) is a complex illness to diag-nose and treat, which presents symptoms that may be part of, or overlap with other diseases or syndromes.The most widely used diagnostic criteria are those of the American College of Rheumatology [1]; no laboratory test has been validated for FMS diagnosis which remains primarily clinically based.Oxidative stress has been proposed as a relevant event in the pathogenesis of FMS with an increase of lipid peroxidation (LPO) [2] and a decrease in vitamin A and E concentrations [3].Although the etiology of FMS remains unclear, genetic predisposition is likely to be an important factor and transmission is thought to be polygenic [4, 5]. If FMS is a multi-genetic disease then it could be hypothesized that differences exist in the type of proteins or protein expres-sion levels in sera of FMS patients compared with healthy controls.Proteomic analysis is a powerful tool for the global evaluation of protein expression and plays a central role in clinical diagnosis and monitoring. Some studies [6] reported interesting proteomic analysis data with an over-expression of transaldolase and phosphoglicerate mutase I in salivary fluid of FMS patients and focused on the role of oxidative stress in the pathogenesis of the disease.The aim of this preliminary study was to evaluate, using two-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS), changes in protein profiles of FMS patients with respect to control subjects to identify potential serum biomarkers useful for disease diagnosis and management.Sixteen females (52 ± 12 years) affected by FMS and 12 healthy females (48 ± 13 years) were enrolled; all patients fulfilled new ACR diagnostic criteria [1] (Table 1). The pres-ence of a major clinical condition other than fibromyalgia was excluded by physical examination and routine blood and urine screening. No patients suffered of thyroid dys-function. Psychiatric examination data of patients were reported in a previous study [7].Study was approved from our Local Ethical Commit-tee and informed consent was obtained from all subjects.Serum protein concentrations were quantified using the PlusOne 2D Quant Kit (GE Healthcare); first dimen-sion isoelectric focusing (IEF) was carried out with 18 cm immobilized pH gradient strips of pH 3–10. The IPG strips were applied onto 10% acrylamide sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) slab gels (25.5 cm × 20.5 cm × 1.0 mm) and overlaid with a solution of 0.5% agarose with a trace of bromophenol blue. Gels were fixed, stained with Coomassie Brilliant Blue G-250 colloi-dal for 24 h and stored at room temperature. At least three sample replicates were performed.2D data were processed with Progenesis SameSpots software, which computed multiplication fold, false dis-covery rate (FDR) q-value, p-values of all spots using one-way ANOVA analysis. A p-value  < 0.05 was considered statistically significant; no difference has been found in protein expression according to patient therapy.After normalization, volume calculation and statisti-cal analysis, same data differences were observed between *Corresponding author: Dr. Antonella Fais, Dipartimento di Scienze della Vita e dell’Ambiente, Università di Cagliari, 09042 Monserrato, Cagliari, Italy, Phone: +39 0706754506, Fax: +39 0706754523, E-mail: fais@unica.itValeria Ruggiero and Enrico Cacace: Dipartimento di Scienze Mediche “Mario Aresu”, Università di Cagliari, Monserrato, Cagliari, ItalyBenedetta Era, Marcella Corda and Stefania Utzeri: Dipartimento di Scienze della Vita e dell’Ambiente, Università di Cagliari, Monserrato, Cagliari, ItalyLaura Molin: CNR-ISTM, Corso Stati Uniti 4, Padova, ItalyBrought to you by | Universita degli Studi di CagliariAuthenticatedDownload Date | 9/30/14 10:34 AMe208      Ruggiero et al.: Proteomic in fibromyalgia syndromeTable 1 Characteristics and scores of the patients and healthy controls examined subjects.  FMS (n = 16)  HC (n = 12)Age, years (mean (SD), range)   52 ± 12 (27–72)  48 ± 13 (27–67)Sex   Females  FemalesMenopause   n = 10  n = 5Body mass index, m2/kg (mean ± SD)   27 ± 5  24 ± 3Duration, month from diagnosis of the disease, mean ± SD   6.3 ± 4.5  –Pain duration, years (mean ± SD)   4.9 ± 0.5  –Pain score patient VAS, mm (mean ± SD)   57 ± 31  –Pain score physician VAS, mm (mean ± SD)   34 ± 18  –FIQ total score, 0–80 (mean ± SD)   61.8 ± 21.9  –Associated clinical distresses Tension type headache   n = 12  – Irritable colon   n = 9  – Oto vestibule syndrome   n = 9  – Paraesthesia   n = 8  – Sleep disturbance   n = 8  – Dysmenorrhea   n = 2  – Hemicrania   n = 4  – Urethral syndrome   n = 5  –Medication No therapy   n = 5  n = 12 Tricyclic, Amitriptyline  < 15 mg/day   n = 6  – Selective serotonin reuptake inhibitors (SSRIs) (Citalopram)   n = 1  – Selective Serotonin Noradrenaline Reuptake Inhibitors (SSNRIs) (Duloxetin)  n = 4  –FIQ, FMS impact questionnaire; VAS, visual analogue scale.Table 2 Identification of 2D-separated proteins. Spot ID  Method   Short name  Accession no.  MW, kDA  pI   Score  Coverage, %  p-Value   Fold-increase  Sequence106  MS   AAT   P01009   46  5.37  91  51  3.228e-005  2.0  K.LVDKFLEDVKK.L                    K.VFSNGADLSGVTEEAPLK.L                    K.VFSNGADLSGVTEEAPLKLSK.A                    K.GKWERPFEVKDTEEEDFHVDQVTTVK.V1065  MS   TTR   P02766   15  5.52  121  100  0.007  1.3  K.AADDTWEPFASGK.T                    R.KAADDTWEPFASGK.T                    K.ALGISPFHEHAEVVFTANDSGPR.R                    K.ALGISPFHEHAEVVFTANDSGPRR.Y                    K.TSESGELHGLTTEEEFVEGIYKVEEIDTK.S2334  MS/MS   RBP4   P02753   23  5.8  70  12  0.039  1.2  R.LIVHNGYCDGRSERNLL.N                    K.GNDDHWIVDTDYDTYAVQYSCR.Lhealthy subjects and patients. In particular, three statisti-cally different spots (106, 1065 and 2334) were highlighted (Table 2) and the related proteins were subsequently iden-tified by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and MS/MS.Protein spots of interest were manually excised from 2-DE gels following the procedure described and adapted by Shevchenko et al. [8]. Identification of proteins was per-formed by peptide-mass fingerprint MALDI/MS measure-ments using a MALDI-TOF/TOF UltrafleXtreme, equipped with 1 kHz smartbeam II laser (λ = 355 nm) and operating in the positive reflectron ion modes. The instrumental con-ditions employed to analyze molecular weight in the m/z range 980–7000 were: Ion Source 1: 25.00 kV; Ion Source 2: 22.40 kV, Lens: 8.00 kV, Reflector: 26.45 kV, Reflector 2: 13.45 kV, Pulsed ion extraction: 120 ns. The matrix employed was α-cyano-4-hydroxycinnamic acid (HCCA) (saturated solution in H2O/Acetonitrile (50:50; v/v) containing 0.1% trifluoroacetic acid (TFA). External mass calibration was performed using the Peptide Calibration Standard, based Brought to you by | Universita degli Studi di CagliariAuthenticatedDownload Date | 9/30/14 10:34 AMRuggiero et al.: Proteomic in fibromyalgia syndrome      e209on the monoisotopic values of [M+H]+ of Angiotensin II, Angiotensin I, Substance P, Bombesin, ACTH clip (1-17), ACTH clip (18-39), Somatostatin 28 at m/z 1046.5420, 1296.6853, 1347.7361, 1619.8230, 2093.0868, 2465.1990 and 3147.4714, respectively. The peptide masses were searched against the National Center for Biotechnology Information non-redundant mammalian (Taxonomy homo sapiens) database using Mascot 2.3 searched from Matrix Science, selecting the Swiss-Prot database. For the present study, protein identification was based on measurements with a Mascot score higher than 55. Minimal expectation for valid identification was p < 0.005 and p < 0.05.The spot ID106 is due to α1-antitrypsin (AAT), spot ID1065 to transthyretin (TTR) and spot ID2334 to retinol binding protein 4 (RBP4) (Mascot database). These iden-tifications were confirmed by MS/MS experiments on selected peptides present in the tryptic digestion mixture of each spot.Immunoprecipitation tests, carried out by auto-mated immunochemistry analyzer, confirmed an increase of identified proteins. No correlation has been found between overexpressed proteins and duration of the disease, VAS or FIQ.For the first time, in this preliminary study some dif-ferences between the human serum protein pattern of FMS patients with respect to healthy controls have been found.The most relevant result is a significant over-expres-sion of three proteins identified by a proteomic approach: TTR, RBP4 and AAT in FMS patients.Oxidative stress has been proposed as a relevant event in the pathogenesis of FMS [2]. A complex defence system protects against oxidative stress including enzymes and non-enzymatic species, such as vitamins C, E and A; vitamin A-bound RBP4 is associated to TTR.Akkus et  al. [3] showed a reduction of vitamin A in FMS patients as a result of its role on radical inhibition and hypothesized an imbalance between ROS production and the antioxidant defence system in patients with fibro-myalgia syndrome. These data might be consistent with a previous study [9] that showed unexpected normal levels of uric acid (despite high levels of inosine, hypoxanthine, xanthine) in FMS patients possibly as a result of its role as a ROS scavenger.Our data show increased serum RBP4; upregulation of RBP4 may induce hypovitaminosis A [10].High serum TTR and RBP4 might be a result of a flow out from the cells due to ROS-mediated alteration of membrane integrity or permeability; in fact, in vivo experiments have suggested that RBP4 also accumulates in vitamin A-deficient hepatocytes but is not secreted into the bloodstream [11].In our study, an overexpression of serum AAT was also observed; Blanco and Coll reported high AAT plasma concentrations in a subset of FMS patients and a signifi-cantly increased number of mast cells (MCs) in the pap-illary dermis of all FMS patients with moderately high levels of AAT [12]. The mastocyte-released chemicals could cause local manifestations (e.g., skin tenderness or pain) that might be related to enhanced pain sensitivity of these patients.A previous study [13] reported a slight increase of AAT associated with a decrease of vitamin A suggest-ing that genetic or environmental factors may influence AAT activity, which is dependent on the antioxidant capacity of liposoluble vitamins. AAT can be oxidized by free radicals released from oxidative stress, result-ing in protein dysfunction that leads to the imbalance between AAT and proteases, which can cause tissue damage [14]. Then there may be high levels of AAT (as reported in our study) but with ineffective action as pro-tease inhibitor.Considering that the TTR and RBP4 are both retinoid transporters, retinoid dysfunction is related to oxida-tive stress as well as AAT. Furthermore, assessment of thiobarbituric acid reactive substances for the measure-ment of lipid peroxidation revealed values over two-fold of the normal range in FMS patients (data not shown), indicating a condition of oxidative stress. These data are in agreement with previous studies that underline the involvement of oxidative stress in the pathology of FMS. Additional studies are required to clarify their exact relationships.Acknowledgments: We thank the patients and the healthy volunteers who participated in this study. The authors would like to thank the University of Vigo for the use of the Progenesis SameSpots software. This study was sup-ported by the RAS–LR7/2007 [grant number CRP-24879] and University of Cagliari.Conflict of interest statementAuthors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research support played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.Research funding: None declared.Employment or leadership: None declared.Honorarium: None declared.Brought to you by | Universita degli Studi di CagliariAuthenticatedDownload Date | 9/30/14 10:34 AMe210      Ruggiero et al.: Proteomic in fibromyalgia syndromeReferences1. Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600–10.2. Castro-Marrero J, Cordero MD, Sáez-Francas N, Jimenez-Gutierrez C, Aguilar-Montilla FJ, Aliste L, et al. Could mitochondrial dysfunction be a differentiating marker between chronic fatigue syndrome and fibromyalgia? Antioxid Redox Signal 2013;19:1855–60.3. Akkus S, Nazıroğlu M, Eris S, Yalman K, Yılmaz N, Yener M.  Levels of lipid peroxidation, nitric oxide, and antioxidant vitamins in plasma of patients with fibromyalgia. Cell Biochem Funct 2009;27:181–5.4. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics 2007;8:67–74.5. Cordero MD, Díaz-Parrado E, Carrión AM, Alfonsi S, Sánchez-Alcazar JA, Bullón P, et al. Is inflammation a mitochondrial dysfunction-dependent event in fibromyalgia? Antioxid Redox Signal 2013;18:800–7.6. Giacomelli C, Bazzichi L, Giusti L, Ciregia F, Baldini C, Da Valle Y, et al. MALDI-TOF e SELDI-TOF: due tecniche “tandem” per l’individuazione di potenziali biomarker nella fibromialgia. Reumatismo 2011;63:165–70.7. Carta MG, Ruggiero V, Sancassiani F, Cutrano F, Manca AR, Peri M, et al. The use of antidepressants in the long-term treatment  should not improve the impact of fibromyalgia on quality of life. Clin Pract Epidemiol Ment Health 2013;9:120–4.8. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850–8.9. Fais A, Cacace E, Corda M, Era B, Peri M, Utzeri S, et al. Purine metabolites in fibromyalgia syndrome. Clin Biochem 2013;46:37–9.10. Chuang C-M, Chang C-H, Wang H-E, Chen K-C, Peng C-C, Hsieh C-L, et al. Valproic acid downregulates RBP44 and elicits hypervitaminosis A-teratogenesis—a kinetic analysis on retinol/retinoic acid homeostatic system. PLoS One 2012;7:e43692.11. Ronne H, Ocklind C, Wiman K, Rask L, Öbrink B, Peterson PA. Ligand-dependent regulation of intracellular protein transport: effect of vitamin a on the secretion of the retinol-binding protein. J Cell Biol 1983;96:907–10.12. Blanco I, Béritze N, Argüelles M, Cárcaba V, Fernández F, Janciauskiene S, et al. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol 2010;29:1403–12.13. Marzatico F, Gaetani P, Tattara F, Bertorelli L, Feletti F, Adinolfi D, et al. Antioxidant status and α1-antiproteinase activity in subarachnoid hemorrhage patients. Life Sci 1998;63:821–4.14. Jamnongkan W, Techasen A, Thanan R, Duenngai K, Sithithaworn P, Mairiang E, et al. Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholan-giocarcinoma. Tumour Biol 2013;34:695–704.Brought to you by | Universita degli Studi di CagliariAuthenticatedDownload Date | 9/30/14 10:34 AM

A preliminary study on serum proteomics in fibromyalgia syndrome

Abstract

Similar works

Full text

Available Versions

Archivio istituzionale della ricerca - Università di Cagliari

Crossref